TB-500: The FDA 503A Vote, Legality, and What the Evidence Actually Shows

TB-500 is not an FDA-approved drug and is not legal to prescribe or compound in the United States today. This page explains a fast-moving regulatory story and the state of the evidence for educational purposes only. It is not medical advice, a recommendation, or encouragement to obtain, supply, or use any substance. Consult a qualified healthcare provider for any medical decision.

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8–6, with one abstention, to recommend that TB-500 be added to the 503A Bulks List — the same margin it gave BPC-157 earlier that day. With both votes in, one peptide influencer summed up the mood: "both halves of the Wolverine Stack made it through the panel."

But the same correction that applied to BPC-157 applies here, and it matters even more for TB-500: eligible is not the same as legal. The committee's "yes" overruled the FDA's own scientists — and for TB-500, the staff's case against it was notably stronger than for BPC-157. This page covers what the vote does and doesn't do, what TB-500 actually is, and why the evidence is thinner than the enthusiasm.

The TB-500 Vote: What Actually Happened

Like BPC-157 and KPV, TB-500 cleared the committee 8–6–1 despite the FDA staff recommending "no" on all seven peptides under review. What sets TB-500 apart is why the staff said no — the objections went beyond "thin data":

• No human effectiveness data for the wound-healing use it was nominated for.
• A cited in-vitro study in which TB-500 did not induce wound healing in fibroblast cultures — a negative result, not just an absence of evidence.
• Immunogenicity risk from peptide aggregation and impurities in injectable products, with no data showing TB-500 avoids it.
• Poor chemical characterization — the FDA found both the free-base and acetate forms are not well characterized, citing inconsistent naming conventions (INN, USAN, IUPAC) and missing data specific to each form.

The committee weighed all that and still recommended inclusion. That gap — between what the evidence shows and what the vote recommends — is the story.

Eligible Does Not Mean Legal

A PCAC recommendation does not make TB-500 legal. The pathway is identical to BPC-157's:

Nothing changed about what you can legally buy the week of the vote. The FDA can still decline the recommendation, and given how pointed its staff's objections to TB-500 were, that outcome is far from ruled out. Today, TB-500 remains an unapproved substance sold only as a "research chemical."

Is TB-500 Legal Right Now?

What Is TB-500?

TB-500 is a synthetic 17-amino-acid fragment of thymosin beta-4 (Tβ4), a naturally occurring protein involved in cell migration, blood-vessel formation, and tissue repair. It is marketed for systemic recovery — tendons, ligaments, muscle, and flexibility — usually by subcutaneous or intramuscular injection.

An important distinction the seller pages tend to blur:

So when a marketing page cites "thymosin beta-4 clinical trials," it is usually pointing at the eye-drop program for a different molecule — not evidence that injected TB-500 heals tendons.

The Evidence: Animal vs Human

The honest read: TB-500's human evidence is weaker than BPC-157's, not stronger. BPC-157 at least has an unpublished Phase 2 ulcerative-colitis signal and a large body of positive animal work; TB-500's file includes a specific negative in-vitro result and unresolved characterization and immunogenicity questions. That is exactly why the FDA staff's objection here was more forceful — and why the 8–6 committee vote is better read as "the risk seems low enough to allow" than "the science is settled."

Why the FDA Said No but the Committee Said Yes

This is the crux, and it mirrors the wider peptide debate. The FDA staff apply a drug-evaluation standard: show effectiveness and safety with quality data. By that bar, TB-500 fails. The committee majority applied a lighter compounding-access standard: is the substance reasonably characterizable and the risk low enough that a prescriber and pharmacy should have the option? Enough members answered yes.

Neither answer means TB-500 "works." It means the committee thought it belonged on a list of things pharmacies may compound if the FDA agrees — which the FDA has not yet done.

Doses Circulating in the Community (No Clinical Validation)

As with BPC-157, search demand for "TB-500 dosage" is high, so let's be direct: there is no validated human dose of TB-500, because no completed human trial has established one. Any protocol is extrapolated from animal work and grey-market convention.

For transparency, the figures that circulate look like this — shown only to describe the phenomenon, not as guidance:

Because these are sold as research chemicals, the reconstitution math is the buyer's, the labeled dose may not match the vial, and there is no quality control. This is not a validated protocol — it is a description of a risk.

Grey-Market Safety Risks

Until (and unless) the FDA finalizes a rule, every TB-500 vial for sale is an unapproved product outside the drug-safety system:

• Immunogenicity. The FDA specifically flagged that injected peptides can trigger immune reactions from aggregation and impurities, and that TB-500 has no data ruling this out.
• Contamination and mislabeling. Third-party testing of research peptides routinely finds wrong contents, incorrect quantities, and bacterial contamination.
• Reconstitution error. A decimal-place mistake in freeze-dried peptide math changes the dose tenfold.
• Sport eligibility. TB-500 and thymosin beta-4 are prohibited at all times under WADA; athletes have been sanctioned.
• "Not for human use" labeling. That disclaimer is a warning, not a technicality.

See the site's standing guidance on grey-market peptides and gray-market retatrutide.

TB-500 vs BPC-157

The two are almost always mentioned together, and both cleared the July 2026 PCAC vote 8–6–1. A quick orientation:

For the full breakdown of BPC-157, see the BPC-157 explainer.

The "Wolverine Stack"

TB-500 and BPC-157 combined are what the peptide community calls the "Wolverine stack" — a nod to comic-book healing. Both halves cleared the FDA committee on the same day, which is why the phrase trended. But the combination has zero human data — stacking two unapproved peptides multiplies the unknowns rather than the benefit. We break down the stack, the circulating "blend" ratios, and why a pre-mixed BPC/TB vial is riskier, not safer, in the Wolverine stack explainer.

How This Relates to GLP-1 Drugs and Retatrutide

TB-500 is a recovery peptide, not a weight-loss drug — it does not act on the GLP-1, GIP, or glucagon receptors that retatrutide and other GLP-1 medications target. The overlap is regulatory and behavioral: the same 503A pathway now debated for TB-500 is the one that made compounded semaglutide available, and TB-500 is commonly stacked alongside GLP-1s to manage joint and soft-tissue complaints during rapid weight loss. See Are Peptides Legal in 2026? for the wider picture.

Unlike TB-500, retatrutide's evidence comes from large published Phase 2 and Phase 3 trials — the two should not be judged by the same standard of proof.

Frequently Asked Questions

Sources

• U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA.gov meeting page
• U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 list). FDA.gov
• World Anti-Doping Agency. 2026 Prohibited List (TB-500 / thymosin beta-4, Section S2). WADA
• Related on this site: BPC-157 · The Wolverine Stack · Are Peptides Legal in 2026? · Grey-Market Peptides